Apixaban (Eliquis) Dosing for Pulmonary Embolism
For acute pulmonary embolism treatment, start apixaban at 10 mg orally twice daily for the first 7 days, then reduce to 5 mg twice daily for the remainder of treatment (minimum 3-6 months). 1
Initial Treatment Phase (Days 1-7)
- Dose: 10 mg orally twice daily
- Duration: Exactly 7 days
- No dose adjustment for renal function, age, or weight during this initial phase 1
- Can be taken with or without food 1
Maintenance Phase (After Day 7)
- Standard dose: 5 mg orally twice daily
- Duration: Minimum 3-6 months for first episode 2, 3
- No routine dose reductions for renal function, age, or weight in VTE treatment 1
Special Populations
Renal Impairment
- CrCl ≥15 mL/min: Use standard dosing (10 mg BID × 7 days, then 5 mg BID) 1
- CrCl <15 mL/min or dialysis: Not recommended by FDA; insufficient data 4, 5
- Important: Unlike atrial fibrillation dosing, VTE treatment does not require dose reduction based on creatinine levels 1
Hepatic Impairment
- Mild (Child-Pugh A): No dose adjustment needed 6
- Moderate (Child-Pugh B): Use with caution; no dose adjustment specified 6
- Severe (Child-Pugh C): Avoid use 6
Age and Weight
- Age ≥80 years: No dose adjustment for PE treatment 1
- Weight ≤60 kg: No dose adjustment for PE treatment 1
- Obesity up to 150 kg: Standard doses are appropriate 7
Extended/Secondary Prevention (After Initial 6 Months)
If continuing anticoagulation beyond 6 months for recurrence prevention:
- Dose: 2.5 mg orally twice daily 1
- This reduced dose is only for extended prophylaxis after completing initial treatment
- Decision to extend should be based on recurrence risk vs. bleeding risk 2, 8
Critical Dosing Distinctions
The PE/DVT dosing differs fundamentally from atrial fibrillation dosing:
- In atrial fibrillation, dose reductions to 2.5 mg BID are required when ≥2 of these criteria are met: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 1
- In PE treatment, these criteria do NOT apply - use full treatment doses regardless 1
Drug Interactions Requiring Caution
- Strong dual P-glycoprotein AND CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): Avoid concomitant use 6, 1
- Strong dual inducers (e.g., rifampin, carbamazepine, phenytoin): Avoid concomitant use 6
- Single pathway inhibitors generally do not require dose adjustment 1
Perioperative Management
- High bleeding risk surgery: Stop 48 hours before (skip 4 doses) 1
- Low bleeding risk surgery: Stop 24 hours before (skip 2 doses) 1
- Restart when adequate hemostasis achieved 1
Missed Dose Protocol
Take as soon as remembered on the same day, then resume twice-daily schedule. Never double the dose 1
Cancer-Associated PE
Apixaban is now an acceptable alternative to low molecular weight heparin for cancer-associated thromboembolism, using the same dosing regimen 9, 7. However, exercise caution with gastrointestinal or urothelial cancers due to increased bleeding risk 7.
Common Pitfall: The most frequent error is inappropriately reducing the dose to 2.5 mg BID during the initial treatment phase based on atrial fibrillation criteria. The 2.5 mg BID dose is only for extended prophylaxis after completing 6 months of treatment, not for acute PE treatment 10, 1.